Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × bemarituzumab × Genitourinary × Clear all

Status

Not yet recruiting 1 No longer available 1 Completed 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

gallium 68 PSMA-11 2 carbon-11 acetate 2 Magnetic Resonance Spectroscopy 2 Axitinib 2 trametinib 1 tazemetostat 1 radium Ra 223 dichloride 1 pegilodecakin 1 omburtamab I-131 1 bicalutamide 1 bemarituzumab 1 apalutamide 1 Suspensions 1 Standard of Care 1 Sodium Acetate 1 Prednisone 1 Prednisolone 1 Powders 1 Paclitaxel 1 N,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acid 1 MLN 8237 1 Everolimus 1 Androgen Antagonists 1 Abiraterone Acetate 1 AM0010 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03801278 2021-12-13

FPA144

Five Prime Therapeutics, Inc.

No longer available

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡